Gao Y - Search Results

1

Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials.

Xiang H, Liu L, Gao Y, Ahene A, Collins H. Xiang H, et al. Among authors: gao y. Cancer Chemother Pharmacol. 2021 Nov;88(5):899-910. doi: 10.1007/s00280-021-04333-y. Epub 2021 Aug 12. Cancer Chemother Pharmacol. 2021. PMID: 34383128 Free PMC article. Clinical Trial.

2

Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.

Lu D, Girish S, Gao Y, Wang B, Yi JH, Guardino E, Samant M, Cobleigh M, Rimawi M, Conte P, Jin JY. Lu D, et al. Among authors: gao y. Cancer Chemother Pharmacol. 2014 Aug;74(2):399-410. doi: 10.1007/s00280-014-2500-2. Epub 2014 Jun 18. Cancer Chemother Pharmacol. 2014. PMID: 24939213 Free PMC article.

3

Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies.

Jin F, Gao Y, Zhou H, Fang L, Li X, Ramanathan S. Jin F, et al. Among authors: gao y. Cancer Chemother Pharmacol. 2016 Jan;77(1):89-98. doi: 10.1007/s00280-015-2891-8. Epub 2015 Dec 8. Cancer Chemother Pharmacol. 2016. PMID: 26645408

4

Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer.

Li C, Wang B, Lu D, Jin JY, Gao Y, Matsunaga K, Igawa Y, Nijem I, Lu M, Strasak A, Chernyukhin N, Girish S. Li C, et al. Among authors: gao y. Cancer Chemother Pharmacol. 2016 Sep;78(3):547-58. doi: 10.1007/s00280-016-3099-2. Epub 2016 Jul 16. Cancer Chemother Pharmacol. 2016. PMID: 27423671

5

Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC).

Chen SC, Kagedal M, Gao Y, Wang B, Harle-Yge ML, Girish S, Jin J, Li C. Chen SC, et al. Among authors: gao y. Cancer Chemother Pharmacol. 2017 Dec;80(6):1147-1159. doi: 10.1007/s00280-017-3443-1. Epub 2017 Oct 17. Cancer Chemother Pharmacol. 2017. PMID: 29043411 Clinical Trial.

6

Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial.

Xiang H, Liu L, Gao Y, Ahene A, Macal M, Hsu AW, Dreiling L, Collins H. Xiang H, et al. Among authors: gao y. Cancer Chemother Pharmacol. 2020 Nov;86(5):595-606. doi: 10.1007/s00280-020-04139-4. Epub 2020 Sep 23. Cancer Chemother Pharmacol. 2020. PMID: 32965540 Free PMC article. Clinical Trial.

7

Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies.

Ou YC, Liu L, Tariq B, Wang K, Jindal A, Tang Z, Gao Y, Sahasranaman S. Ou YC, et al. Among authors: gao y. Clin Transl Sci. 2021 Mar;14(2):764-772. doi: 10.1111/cts.12948. Epub 2021 Jan 25. Clin Transl Sci. 2021. PMID: 33306268 Free PMC article.

8

Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease.

Xin Y, Xu F, Gao Y, Bhatt N, Chamberlain J, Sile S, Hammel S, Holt RJ, Ramanathan S. Xin Y, et al. Among authors: gao y. Clin Pharmacokinet. 2021 Aug;60(8):1029-1040. doi: 10.1007/s40262-021-01003-3. Epub 2021 Mar 26. Clin Pharmacokinet. 2021. PMID: 33768488 Free PMC article.

9

Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma.

Ou YC, Tang Z, Novotny W, Cohen A, Wang K, Liu L, Gao Y, Sahasranaman S. Ou YC, et al. Among authors: gao y. Leuk Lymphoma. 2021 Nov;62(11):2612-2624. doi: 10.1080/10428194.2021.1929961. Epub 2021 Jun 23. Leuk Lymphoma. 2021. PMID: 34159878 Free article. Clinical Trial.

10

Model-based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors.

Budha N, Wu CY, Tang Z, Yu T, Liu L, Xu F, Gao Y, Li R, Zhang Q, Wan Y, Sahasranaman S. Budha N, et al. Among authors: gao y. CPT Pharmacometrics Syst Pharmacol. 2023 Jan;12(1):95-109. doi: 10.1002/psp4.12880. Epub 2022 Nov 23. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36330700 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

46,023 results

Search Page

Filters